Charles River Laboratories International Inc logo

Charles River Laboratories International Inc CRL

Market Closed
21 Jun, 20:00
NYSE NYSE
$
211. 60
+1.97
+0.94%
After Hours
$
211. 60
-0.05 -0.02%
10.94B Market Cap
25.59 P/E Ratio
0% Div Yield
681,800 Volume
11.02 Eps
$ 209.63
Previous Close
Day Range
208.69 212.3
Year Range
161.65 275

CRL Chart

Charles River Laboratories International Inc Profile

Diagnostics & Research Industry
Healthcare Sector
Mr. James C. Foster J.D. CEO
NYSE Exchange
US1598641074 ISIN
US Country
20,400 Employees
- Last Dividend
- Last Split
23 Jun 2000 IPO Date

Overview

Charles River Laboratories International, Inc., established in 1947 and headquartered in Wilmington, Massachusetts, is a global provider of essential services to advance the drug discovery, non-clinical development, and safety testing fields. The company's extensive portfolio of services is offered in the United States, Europe, Canada, the Asia Pacific, and other international locations. It operates through three main segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each addressing different stages and needs in the pharmaceutical and biotechnological development process.

Products and Services

  • Research Models and Services (RMS):
  • This segment specializes in producing and selling rodents, including purpose-bred rats and mice, for research purposes. It supports its clients with a range of services aimed at enhancing the use of research models in scientific investigation and pre-clinical drug candidate screening. The offerings include the provision of research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The RMS segment is designed to facilitate the seamless integration of high-quality research models into the drug development pipeline.

  • Discovery and Safety Assessment (DSA):
  • The DSA segment provides a suite of early discovery and in vivo services for identifying and validating new targets, chemical compounds, and antibodies. This wide array of services extends to delivering preclinical drug and therapeutic candidates that are ready for safety assessment. Additionally, this segment offers comprehensive safety assessment services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. These are crucial for ensuring the safety and efficacy of drug candidates before they proceed to clinical trials.

  • Manufacturing Solutions (Manufacturing):
  • This segment caters to the needs for in vitro methods for quality control testing of both sterile and non-sterile pharmaceuticals and consumer products. It encompasses specialized testing services for biologics, which are often outsourced by pharmaceutical and biotechnology companies. Beyond traditional testing services, the Manufacturing segment also provides contract vivarium operation services, offering biopharmaceutical clients the infrastructure and expertise necessary for the effective management of their vivarium facilities.

Contact Information

Address: 251 Ballardvale Street, Wilmington, MA, United States, 01887
Phone: 781 222 6000